Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pomalidomide
Drug ID BADD_D01798
Description Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Indications and Usage Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Marketing Status approved
ATC Code L04AX06
DrugBank ID DB08910
KEGG ID D08976
MeSH ID C467566
PubChem ID 134780
TTD Drug ID D0A3ZU
NDC Product Code 65015-893; 17337-0068; 63069-404; 68554-0092; 70225-1106; 59572-501; 59572-502; 55111-989; 68554-0091; 82245-0108; 63069-402; 42973-232; 54893-0038; 59572-503; 59572-504; 63069-403
UNII D2UX06XLB5
Synonyms pomalidomide | CC-4047 | CC 4047 | CC4047 | Imnovid | Pomalyst | actimid
Chemical Information
Molecular Formula C13H11N3O4
CAS Registry Number 19171-19-8
SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Multiple organ dysfunction syndrome08.01.03.057--
Abdominal mass07.01.01.0030.000940%Not Available
Blood blister12.01.06.013; 23.03.01.0280.000940%Not Available
Bone cancer16.29.02.002; 15.09.03.0120.000603%Not Available
Central nervous system lymphoma18.04.04.013; 17.02.10.028; 16.20.01.005; 01.12.01.0050.000530%Not Available
Chronic respiratory failure22.02.06.005; 14.01.04.0050.000362%Not Available
Jugular vein thrombosis24.01.02.0070.000362%Not Available
Malignant pleural effusion22.05.04.001; 16.32.03.0140.000362%Not Available
Pulmonary artery thrombosis24.01.06.005; 22.06.02.0050.000241%Not Available
Strangulated hernia24.04.02.025; 08.01.04.0050.000241%Not Available
Vertebral lesion15.02.04.0400.000241%Not Available
Neck mass15.03.02.0070.001350%Not Available
Semen discolouration21.03.03.0080.000820%Not Available
Ocular neoplasm16.34.03.001; 06.12.03.0010.000241%Not Available
Secondary immunodeficiency10.03.03.0090.000362%Not Available
Appendix disorder07.11.01.0200.000482%Not Available
Aortic valve disease02.07.03.0020.000241%
Perforated ulcer08.03.06.0020.000241%Not Available
Spinal cord neoplasm17.20.01.009; 16.30.01.0090.000482%Not Available
Spider vein23.06.03.006; 24.10.04.0030.001230%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000241%Not Available
Lip exfoliation07.05.05.0200.000820%Not Available
Nail growth abnormal23.02.05.0240.000820%Not Available
Weight bearing difficulty15.03.05.0340.000530%Not Available
Heart valve incompetence02.07.02.0030.000530%Not Available
Basal ganglia infarction24.04.06.028; 17.08.01.0400.000241%Not Available
Bone deformity15.10.03.0060.000820%Not Available
Seizure like phenomena17.12.03.0300.000241%Not Available
Plasma cell myeloma recurrent16.23.02.006; 01.14.02.0060.019844%Not Available
Pulmonary pain22.12.01.0100.001230%Not Available
The 15th Page    First    Pre   15 16    Next   Last    Total 16 Pages